| Machine learning in drug discovery and development Part 1: a primer A Talevi, JF Morales, G Hather, JT Podichetty, S Kim, PC Bloomingdale, ... CPT: pharmacometrics & systems pharmacology 9 (3), 129-142, 2020 | 52 | 2020 |
| Precompetitive consensus building to facilitate the use of digital health technologies to support parkinson disease drug development through regulatory science D Stephenson, R Alexander, V Aggarwal, R Badawy, L Bain, R Bhatnagar, ... Digital biomarkers 4 (1), 28-49, 2020 | 43 | 2020 |
| A systems pharmacology model for drug delivery to solid tumors by antibody-drug conjugates: implications for bystander effects JK Burton, D Bottino, TW Secomb The AAPS journal 22 (1), 1-13, 2020 | 29 | 2020 |
| Disease persistence in epidemiological models: the interplay between vaccination and migration J Burton, L Billings, DAT Cummings, IB Schwartz Mathematical biosciences 239 (1), 91-96, 2012 | 29 | 2012 |
| Open data revolution in clinical research: Opportunities and challenges MH Shahin, S Bhattacharya, D Silva, S Kim, J Burton, J Podichetty, ... Clinical and translational science 13 (4), 665-674, 2020 | 24 | 2020 |
| Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy K Lingineni, V Aggarwal, JF Morales, DJ Conrado, D Corey, C Vong, ... CPT: pharmacometrics & systems pharmacology 11 (3), 318-332, 2022 | 17 | 2022 |
| Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy DJ Conrado, J Larkindale, A Berg, M Hill, J Burton, KR Abrams, ... Journal of pharmacokinetics and pharmacodynamics 46 (5), 441-455, 2019 | 17 | 2019 |
| Molecular neuroimaging of the dopamine transporter as a patient enrichment biomarker for clinical trials for early parkinson's disease K Romero, D Conrado, J Burton, T Nicholas, V Sinha, S Macha, ... Clinical and translational science 12 (3), 240-246, 2019 | 16 | 2019 |
| Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs M Ahamadi, DJ Conrado, S Macha, V Sinha, J Stone, J Burton, T Nicholas, ... Clinical Pharmacology & Therapeutics 107 (3), 553-562, 2020 | 15 | 2020 |
| Challenges in Alzheimer's Disease Drug Discovery and Development: the role of modeling, simulation, and open data DJ Conrado, S Duvvuri, H Geerts, J Burton, C Biesdorf, M Ahamadi, ... Clinical Pharmacology & Therapeutics 107 (4), 796-805, 2020 | 12 | 2020 |
| Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth K Johnson, A Gomez, J Burton, D White, A Chakravarty, A Schmid, ... European Journal of Cancer 109, 196-203, 2019 | 12 | 2019 |
| Leveraging Real‐World Data for EMA Qualification of a Model‐Based Biomarker Tool to Optimize Type‐1 Diabetes Prevention Studies JT Podichetty, P Lang, IM O’Doherty, SE David, RN Muse, SR Karpen, ... Clinical Pharmacology & Therapeutics 111 (5), 1133-1141, 2022 | 9 | 2022 |
| Identifying and characterising sources of variability in digital outcome measures in Parkinson’s disease G Roussos, TR Herrero, DL Hill, AV Dowling, M LTM Müller, LJW Evers, ... npj Digital Medicine 5 (1), 1-10, 2022 | 7 | 2022 |
| Innovations in Therapy Development for Rare Diseases Through the Rare Disease Cures Accelerator-Data and Analytics Platform J Larkindale, A Betourne, A Borens, V Boulanger, V Theurer Crider, ... Therapeutic Innovation & Regulatory Science, 1-9, 2022 | 7 | 2022 |
| Standardized data structures in rare diseases: CDISC user guides for Duchenne muscular dystrophy and Huntington’s disease AP Mullin, D Corey, EC Turner, R Liwski, D Olson, J Burton, ... Clinical and Translational Science 14 (1), 214-221, 2021 | 7 | 2021 |
| Open data for clinical pharmacology J Burton, S Bhattacharya, K Romero, DJ Conrado Clinical Pharmacology & Therapeutics 107 (4), 703-706, 2020 | 7 | 2020 |
| Drug development tools in the alzheimer disease continuum (ddt-ad) working group. challenges in Alzheimer's Disease drug discovery and development: the role of modeling … DJ Conrado, S Duvvuri, H Geerts, J Burton, C Biesdorf, M Ahamadi, ... Clin Pharmacol Ther 107 (4), 796-805, 2020 | 6 | 2020 |
| Critical Path for Parkinson’s (CPP) Consortium. Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson’s disease to inform clinical trial designs M Ahamadi, DJ Conrado, S Macha, V Sinha, J Stone, J Burton, T Nicholas, ... Clinical Pharmacology and Therapeutics 107, 553-562, 2020 | 5 | 2020 |
| Recommendations to optimize the use of volumetric MRI in Huntington's disease clinical trials KM Kinnunen, AP Mullin, D Pustina, E Turner, J Burton, MF Gordon, ... Frontiers in Neurology, 1867, 0 | 5 | |
| Theoretical models for drug delivery to solid tumors JK Burton III The University of Arizona, 2016 | 4 | 2016 |
